Background: The effectiveness of neoadjuvant immunochemotherapy (NAIC) in treating resectable locally advanced oral squamous cell carcinoma (LAOSCC) remains uncertain, with a notable lack of precise ...

A comparison of TPS 1-49% vs ≥50% showed a big improvement with the higher TPS for oleclumab-durvalumab (5.6% vs 32.0%) and smaller increases with monalizumab-durvalumab (30.0% vs 35.0%) and ...

Response-Adapted Surgical and Radiotherapy De-Escalation in Resectable Cutaneous Squamous Cell Cancer Using Pembrolizumab: The De-Squamate Study The following represents disclosure information ...

The Food and Drug Administration (FDA) has approved Keytruda ® (pembrolizumab) for the treatment of patients with resectable (tumors ≥4cm or node positive) non-small cell lung cancer (NSCLC) in ...

Key Takeaways Imfinzi combined with FLOT chemotherapy improved EFS in resectable gastric/GEJ adenocarcinoma, with no new safety signals observed. Adverse effects were comparable between Imfinzi and ...

Source Reference: Reyngold M, et al "Nonoperative management of technically resectable pancreatic cancer with ablative radiation therapy" JAMA Oncol 2025; DOI: 10.1001/jamaoncol.2025.0460.

“Today’s approval of Imfinzi in resectable early-stage lung cancer builds on its strong foundation of changing clinical practice in unresectable stage III disease,” said Dave Fredrickson ...

MADRID — The addition of nivolumab to neoadjuvant chemotherapy, followed by adjuvant nivolumab, improved outcomes for patients with untreated resectable non-small cell lung cancer, randomized ...

The addition of preoperative chemoradiotherapy to standard perioperative chemotherapy did not improve survival for certain patients with resectable gastric cancer, according to results of a ...

Patients with borderline resectable pancreatic cancer (PDAC) are often treated with chemotherapy, radiotherapy, or both before undergoing surgery, but the optimal regimen in this setting is ...